23andMe Holding Co. (NASDAQ:ME) Sees Large Decline in Short Interest

23andMe Holding Co. (NASDAQ:ME) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 950,200 shares, a decrease of 16.6% from the November 15th total of 1,140,000 shares. Based on an average daily volume of 325,600 shares, the days-to-cover ratio is presently 2.9 days. Currently, 5.9% of the shares of the stock are short sold.

23andMe Trading Up 0.6 %

Shares of NASDAQ:ME opened at $3.35 on Monday. 23andMe has a twelve month low of $2.65 and a twelve month high of $20.40. The firm has a market cap of $87.50 million, a P/E ratio of -0.13 and a beta of 1.15. The company has a 50 day moving average of $4.33 and a 200-day moving average of $6.54.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%. The firm had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC grew its holdings in shares of 23andMe by 410.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after acquiring an additional 71,204 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in 23andMe during the 2nd quarter worth about $43,000. Levin Capital Strategies L.P. purchased a new stake in 23andMe during the second quarter valued at about $61,000. AQR Capital Management LLC boosted its holdings in shares of 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock worth $174,000 after buying an additional 263,468 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of 23andMe in the second quarter worth approximately $203,000. 36.10% of the stock is owned by institutional investors and hedge funds.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.